Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Justin S. Bryans"'
Autor:
Marion MacFarlane, Catherine A. Kettleborough, Catrin Pritchard, Meeta Patel, Lynne M. Howells, Justin S. Bryans, Tim Hammonds, Howard Pringle, Ian R. Powley, Anne Thomas, Gareth J Miles
Publikováno v:
British Journal of Cancer
Preclinical models that can accurately predict outcomes in the clinic are much sought after in the field of cancer drug discovery and development. Existing models such as organoids and patient-derived xenografts have many advantages, but they suffer
Publikováno v:
Expert Opinion on Drug Discovery. 14:605-607
Autor:
Robert Cassels, Jack E. Baldwin, Christopher J. Schofield, Timothy J. Sewell, Matthew D. Lloyd, Robert M. Adlington, Justin S. Bryans, Keith H. Baggaley
Incubation of the γ-lactam analogue of proclavaminic acid, (±)-threo-5-amino-3-hydroxy-2-(1′-aza-2′-oxocyclopentyl)-pentanoic acid, led to production of two bicyclic γ-lactam products.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa46150eee1df003045013821443d025
https://doi.org/10.1016/s0040-4020(97)00399-2
https://doi.org/10.1016/s0040-4020(97)00399-2
Autor:
Justin S. Bryans, Keith H. Baggaley, Jack E. Baldwin, Timothy J. Sewell, Christopher J. Schofield, Matthew D. Lloyd, Robert M. Adlington, Robert Cassels
Incubation of a γ-lactam analogue of proclavaminic acid with clavaminic acid synthase, gave two novel bicyclic γ-lactams.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6a86dd5ccae8edb10efa16f3931947d
https://ora.ox.ac.uk/objects/uuid:24f4c400-30bf-4a02-89f9-933559de2424
https://ora.ox.ac.uk/objects/uuid:24f4c400-30bf-4a02-89f9-933559de2424
Autor:
Jasveen Chugh, David Whalley, Timothy J. Nott, Roger S. Buxton, Nathalie Bouloc, Barbara Saxty, Justin S. Bryans, Tim Chapman, Simon A. Osborne, Stephen J. Smerdon, Debra L. Taylor, Dony Patel, Vicky L. Spivey, Kathryn E.A. Lougheed, Catherine A. Kettleborough
Publikováno v:
Tuberculosis (Edinburgh, Scotland)
Summary PknB is an essential serine/threonine kinase of Mycobacterium tuberculosis with possible roles in a number of signalling pathways involved in cell division and metabolism. We screened a library of >50,000 compounds for inhibitors of the in vi
Publikováno v:
Tuberculosis. 89:364-370
summary Mycobacterium tuberculosis has an on-going impact on global public health and new therapeutics to treat tuberculosis are urgently required. The emergence of drug resistant tuberculosis poses a serious threat to the control of this pathogen, a
Autor:
Nathalie Bouloc, Jonathan M. Large, Ela Smiljanic, Christopher David Edlin, Keith H. Ansell, Justin S. Bryans, David Whalley
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:5294-5298
A high-throughput screening campaign identified a number of imidazopyridazines as novel inhibitors of the malarial kinase PfPK7. Further synthetic chemistry efforts enabled the preparation of a number of analogues with promising in vitro potencies. A
Autor:
Lee Dawson, David Bowman, Jane Elsom, Justin S. Bryans, Simon H. Ridley, Rosa M. Sancho, Duncan Young, Nigel M. Hooper, Beth Sivyer, Eric Karran, Andy Takle, Michael Hutton
Publikováno v:
Alzheimer's & Dementia. 10
Autor:
Roberto Solari, Debbie Taylor, Justin S. Bryans, Catherine A. Kettleborough, Michael Dalrymple
Publikováno v:
Expert opinion on drug discovery. 1(1)
The movement of ideas and innovation from academia into the world of business has a long and fruitful history. Ironically, it might be argued that the recent pressure put on universities and basic research organisations to protect and exploit their i
Autor:
Ahmad Kamal, Jasveen Chugh, Michelle Newman, William Tsang, Debra L. Taylor, Edward G. McIver, Kristian Birchall, Philip Cohen, Alison Levy, Justin S. Bryans, Kristopher Clark, J. Simon C. Arthur, Joanne Osborne, Stephen John Lewis, Tom Drake, Ela Smiljanic-Hurley
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(23)
The design, synthesis and structure-activity relationships of a novel series of 2,4-diamino-5-cyclopropyl pyrimidines is described. Starting from BX795, originally reported to be a potent inhibitor of PDK1, we have developed compounds with improved s